Apply evolving standards of care in the treatment of GI cancers by integrating current evidence and expert consensus across diverse disease states including esophageal, gastric, pancreatic, hepatocellular, cholangiocarcinoma, and colorectal cancers.
Evaluate the role of surgery, radiation, and systemic therapy in curative, borderline, and advanced settings, with emphasis on case-based application and disease-specific considerations.
Incorporate molecular profiling and liquid biopsy techniques into diagnostic workflows, minimal residual disease (MRD) monitoring, and therapeutic decision-making.
Differentiate the clinical utility of immunotherapies and targeted therapies—including checkpoint inhibitors, FGFR inhibitors, HER2-targeted agents, and novel combinations—in early-stage and advanced GI malignancies.
Critically analyze real-world case discussions to develop personalized, evidence-based treatment plans for special patient populations, including those with comorbidities, germline mutations, or rare tumor types.
Discuss emerging therapies and future directions in GI oncology, including novel agents in development, tumor treating fields (TTFs), and precision treatment strategies projected for the next decade.
Interpret controversies and clinical trial evidence through moderated debates and expert panels, fostering nuanced understanding of differing approaches such as FLOT vs CROSS or the role of radiation in pancreatic and esophageal cancers.
Identify strategies to optimize multidisciplinary collaboration among oncologists, surgeons, radiologists, pathologists, and palliative care providers to enhance care delivery in complex GI oncology scenarios.

2026 MaTOS GI | Faculty PDF Access

Tracking MRD, Tumor Informed vs Agnostic Approaches Which One is Better?

Tracking MRD, Tumor Informed vs Agnostic Approaches Which One is Better? Attachments